Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454532
Status:
COMPLETED
Last Update Posted:
2012-03-16
First Post:
2007-03-26
Brief Title:
A Phase III Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
Sponsor:
Bionovo
Organization:
Bionovo
Study Overview
Official Title:
A Phase III Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BZL 101 is an aqueous extract from herba Scutellaria Barbata D Don of the Lamiaceae family Preclinical studies suggest that this herb has antitumor activity for breast cancer and preliminary clinical data suggest that it is tolerable in patients with metastatic breast cancer The overall goals of this Phase III trial are to assess the toxicity maximum tolerated dose safety and preliminary efficacy of BZL101 for the treatment of advanced metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None